Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 19,416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination Clear all
Completed Phase 1Phase 2 Interventional Results available

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032
View directory record Official record
Conditions
Thalassemia Major With Severe Transfusional Iron Overload
Interventions
Deferasirox and deferiprone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00028587
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

NCT04274907
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cancer
Interventions
Venetoclax, Pembrolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 23, 2026, 4:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Targeted Lower Extremity Joint Training

NCT00765544
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anklebot, Lokomat
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 23, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834
View directory record Official record
Conditions
Melanoma
Interventions
Elesclomol (STA-4783), Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 23, 2026, 4:42 AM EDT
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 75 Years
Enrollment
15,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 23, 2026, 4:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT05312411
View directory record Official record
Conditions
Osteosarcoma
Interventions
SCRI-E2CAR_EGFRtv1, UB_TT170
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

NCT03146871
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Brain Connections and Blood Pressure

NCT03736434
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Mindfulness and DASH Diet Education, Education group
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
65 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Targeted Fusion Biopsy of the Prostate

NCT02744534
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 23, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892
View directory record Official record
Conditions
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Does a ThoracoLumbar Interfacial Plane (TLIP) Block With Liposomal Bupivacaine Provide TLIP Block in Spinal Surgery

NCT04865211
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal bupivacaine, Bupivacaine Injection, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

NCT00332644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 23, 2026, 4:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT06460298
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

NCT00003298
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
30
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of Onnit Alpha Brain on Cognition and Mood States

NCT07495592
View directory record Official record
Conditions
Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition), Fatigue
Interventions
Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement, Controlled Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
20 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Recruiting Not applicable Interventional

Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique

NCT02708836
View directory record Official record
Conditions
Limit Emergence Phenomena After General Anesthesia
Interventions
Induction of anesthesia, Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask], Laryngoscopy and placement of ETT, Ventilation via the ETT, Removal of the ETT, Intubation of the trachea through the LMA, Ventilation via the LMA, Emergence from anesthesia
Procedure · Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 4 Interventional Results available

Postoperative Pain Control in Septum and Sinus Surgery

NCT04149964
View directory record Official record
Conditions
Post-operative Pain, Sinus Surgery
Interventions
Acetaminophen 325 mg Oral Tablet, Acetaminophen 650 mg Oral Tablet, OxyCODONE 5 mg Oral Tablet, Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 23, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

NCT05294328
View directory record Official record
Conditions
Presbyopia, Refractive Errors, Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Glendale, California • Indianapolis, Indiana • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 23, 2026, 4:42 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

NCT07604285
View directory record Official record
Conditions
Glioblastoma
Interventions
MT-125
Drug
Lead sponsor
Myosin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 4:42 AM EDT
Recruiting No phase listed Observational

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

NCT04509050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
Sonya Heltshe
Other
Eligibility
Up to 10 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 4:42 AM EDT